OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $9.06.

OPRX has been the topic of a number of analyst reports. Stephens initiated coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective on the stock. JMP Securities decreased their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 14th. Barclays decreased their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 14th. B. Riley decreased their price target on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Finally, Stifel Nicolaus decreased their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

Insider Transactions at OptimizeRx

In related news, CEO William J. Febbo bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares during the period. Quest Partners LLC raised its holdings in shares of OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares during the period. Connors Investor Services Inc. raised its holdings in shares of OptimizeRx by 15.1% during the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after buying an additional 2,500 shares during the period. Barclays PLC raised its holdings in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in OptimizeRx during the 2nd quarter worth approximately $282,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Stock Down 7.0 %

OPRX opened at $5.41 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market cap of $99.66 million, a P/E ratio of -4.07 and a beta of 1.36. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65. The business’s fifty day simple moving average is $5.16 and its 200 day simple moving average is $7.25.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.